Abstract Background: Cancer-related symptoms such as pain, sleep disturbances, anxiety, and gastrointestinal (GI) complaints often negatively impact patients’ quality of life. Patient-Reported Outcomes Measurement Information System (PROMIS) instruments were developed to quantify these domains and provide standardized, validated measures for clinical interventions. Given the growing interest in cannabis as an adjunctive therapy, we sought to determine whether guided cannabis care could enhance PROMIS-defined symptom outcomes among individuals with active cancer diagnoses. Methods: A total of 52 patients were enrolled from multiple oncology centers, dedicated marketing efforts, and various cancer advocacy organizations. At baseline, each patient completed PROMIS assessments for Pain Interference, Sleep Disturbance, Anxiety, and GI Nausea 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS1-01-27.
Worster et al. (Tue,) studied this question.